BR112014031123A2 - gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits and compulsive behaviors associated with neuropsychiatric and neurodevelopmental disorders and pharmaceutical composition containing gastrin-releasing peptide - Google Patents

gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits and compulsive behaviors associated with neuropsychiatric and neurodevelopmental disorders and pharmaceutical composition containing gastrin-releasing peptide

Info

Publication number
BR112014031123A2
BR112014031123A2 BR112014031123A BR112014031123A BR112014031123A2 BR 112014031123 A2 BR112014031123 A2 BR 112014031123A2 BR 112014031123 A BR112014031123 A BR 112014031123A BR 112014031123 A BR112014031123 A BR 112014031123A BR 112014031123 A2 BR112014031123 A2 BR 112014031123A2
Authority
BR
Brazil
Prior art keywords
gastrin
releasing peptide
neuropsychiatric
treatment
neurodevelopmental disorders
Prior art date
Application number
BR112014031123A
Other languages
Portuguese (pt)
Inventor
Schwartsmann Gilberto
Michelin Becker Michele
Roesler Rafael
Dos Santos Riesgo Rudimar
Original Assignee
Schwartsmann Gilberto
Roesler Rafael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwartsmann Gilberto, Roesler Rafael filed Critical Schwartsmann Gilberto
Publication of BR112014031123A2 publication Critical patent/BR112014031123A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

resumo métodos baseados em receptor do peptídeo liberador de gastrina para o tratamento de estereotipias, déficits de comportamento social e comportamentos compulsivos associados a transtornos neuropsiquiátricos e de desenvolvimento neurológico e composição farmacêutica contendo peptídeo de liberação de gastrina a presente invenção, no campo de tratamento de sintomas de transtornos neuropsiquiátricos e de desenvolvimento neurológico, proporciona métodos para o tratamento de sintomas incluindo estereotipias, déficits de comportamento social e comportamentos obsessivos em um sujeito afligido com distúrbios neuropsiquiátrico ou neurodesenvolvimental. os métodos compreendem a administração a um sujeito de uma quantidade terapeuticamente eficaz do peptídeo de libertação da gastrina (grp) ou outro receptor agonista de grp (grpr). 1/1Gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits and compulsive behaviors associated with neuropsychiatric and neurodevelopmental disorders and pharmaceutical composition containing gastrin-releasing peptide of the present invention in the field of symptom treatment Neuropsychiatric and neurodevelopmental disorders, provides methods for the treatment of symptoms including stereotypes, social behavior deficits and obsessive behaviors in a subject afflicted with neuropsychiatric or neurodevelopmental disorders. The methods comprise administering to a subject a therapeutically effective amount of the gastrin release peptide (grp) or other grp agonist receptor (grpr). 1/1

BR112014031123A 2012-06-11 2012-06-11 gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits and compulsive behaviors associated with neuropsychiatric and neurodevelopmental disorders and pharmaceutical composition containing gastrin-releasing peptide BR112014031123A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2012/000182 WO2013185187A1 (en) 2012-06-11 2012-06-11 Gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits, and compulsive behaviors associated with neuropsychiatry and neurodevelopmental disorders and pharmaceutical composition containing grp

Publications (1)

Publication Number Publication Date
BR112014031123A2 true BR112014031123A2 (en) 2017-06-27

Family

ID=49757339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031123A BR112014031123A2 (en) 2012-06-11 2012-06-11 gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits and compulsive behaviors associated with neuropsychiatric and neurodevelopmental disorders and pharmaceutical composition containing gastrin-releasing peptide

Country Status (2)

Country Link
BR (1) BR112014031123A2 (en)
WO (1) WO2013185187A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513702A (en) * 2002-09-09 2006-04-27 ヌラ インコーポレーティッド G protein-coupled receptor and use thereof
US20080051315A1 (en) * 2003-12-11 2008-02-28 Eric Kandel Grp Receptor-Related Methods for the Treating and Preventing Fear-Related Disorders
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof

Also Published As

Publication number Publication date
WO2013185187A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
EA201591403A1 (en) SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION
CU20140082A7 (en) PYRIMIDINES AND FUSIONATED TRIAZINS REPLACED AND THEIR USE
BR112012028136A2 (en) combination therapy
CR20140142A (en) VARIANTS OF THE FIBROBLAST GROWTH 21
CO6791571A2 (en) Modulators of protein tyrosine kinase 7 (ptk7) for the diagnostic treatment or prophylaxis of neoplastic disorders
CL2014001080A1 (en) Compounds derived from n-urea-substituted amino acid amide, type-1 receptor modulators (fprl-1), useful in the treatment of eye conditions.
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
IN2014DN07752A (en)
CL2015002485A1 (en) Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases
CR20110509A (en) PHARMACEUTICAL COMPOSITION
CL2014001994A1 (en) Synthetic apeline mimetic polypeptide for treatment and heart failure; pharmaceutical composition comprising said polypeptide.
CL2008002744A1 (en) Compounds derived from 1,3-disubstituted-4-phenyl-1h-pyridin-2-one, allosteric modulators of the glutamatergic receptor mglur2; Pharmaceutical composition and use of the compounds in the treatment of neurological and psychiatric conditions mediated by mglur2.
CL2013003816A1 (en) Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases.
RU2018145985A (en) ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS
BR112018005223A2 (en) compounds and methods for modulating angiotensinogen expression
BR112016011789A2 (en) PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND THEIR USE
CO6551683A2 (en) TREATMENT FOR GASTROINTESTINAL DISORDERS
CO6531464A2 (en) MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7
BR112013029256A8 (en) pharmaceutical combination for use in treating patients with type 2 diabetes
AR088083A1 (en) USE OF ANION BODIES TO IL-1b
BR112019012071A2 (en) treating a gastrointestinal tract disease with an integrin inhibitor
CO2017012622A2 (en) Positive allosteric modulators of the muscarinic receptor m2
UY32734A (en) 1-PHOSPHATE RECEPTOR AGONIST COMPOUNDS
BR112014005025A2 (en) pharmaceutical composition for use in the treatment of a neurodegenerative disease
HRP20221098T1 (en) Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements